Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction.
Cardiovasc Ther
January 2025
Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Article Synopsis
- Heart failure and renal dysfunction often occur together, creating complex interactions that negatively affect patient outcomes.
- The drug sacubitril/valsartan shows promise in improving heart and kidney health in heart failure patients with reduced ejection fraction, potentially slowing kidney function decline.
- However, more evidence is needed to confirm its safety in preventing hyperkalemia and worsening kidney function, emphasizing the need for personalized treatment strategies and further research into heart-kidney interactions.
A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS).
Sci Rep
December 2024
Department of Comprehensive Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and angioedema. Sacubitril/valsartan-associated ototoxicity is often underreported in clinical studies and real-world settings.
View Article and Find Full Text PDFMelatonin attenuates responses to angiotensin II in isolated aortic rings of STZ-induced type 1-like DM rats.
Endocr Res
December 2024
Department of Biology, College of Science, Salahaddin University-Erbil, Erbil, Kurdistan Region, Iraq.
Background: In patients with diabetes mellitus (DM), vascular endothelial dysfunction (VED) is the main reason for impaired life expectancy. Melatonin (MEL) demonstrates wide-ranging effects across various organs and exhibits pleiotropic characteristics. The current study aims to investigate the modulatory roles of MEL vascular response to angiotensin II (Ang II) and its receptors including angiotensin type 1 receptor (AT-1 R) and angiotensin type 2 receptor (AT-2 R) in isolated thoracic aorta of non-diabetes (non-DM) and diabetes (DM) rats.
View Article and Find Full Text PDFDrug-induced dementia: a pharmacovigilance analysis of the FAERS database.
Expert Opin Drug Saf
December 2024
Department of Pharmacy, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Background: Dementia is a global public health challenge. Certain medications, such as anticholinergics and benzodiazepines, have been linked to an increased dementia risk. However, most studies focused on a limited range of drugs, lacking a comprehensive overview.
View Article and Find Full Text PDFIntegrating Metabolomics, Histopathology, and Cardiac Marker Analysis to Assess Valsartan's Efficacy in Mitigating Dasatinib-Induced Cardiac Toxicity in Sprague-Dawley Rats.
Drug Des Devel Ther
December 2024
Department of Pharmacology & Toxicology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Background: Dasatinib (DASA) is associated with cardiotoxic effects, posing risks to patients. Valsartan (VAL) may offer protective benefits against these effects. This study evaluates the impact of DASA, VAL, and their combination on cardiac health.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!